AP NEWS
Press release content from Business Wire. The AP news staff was not involved in its creation.
PRESS RELEASE: Paid content from Business Wire
Press release content from Business Wire. The AP news staff was not involved in its creation.

MedinCell: Publication of the Activity Report and Financial Information for the First Half-year (April - Sept. 2019)

December 3, 2019 GMT

MONTPELLIER, France--(BUSINESS WIRE)--Dec 3, 2019--

MedinCell (Paris:MEDCL):

Progression of the portfolio with FDA IND clearance to initiate clinical activities for mdc-TJK and mdc-ANG entering preclinical

Launch of Animal Health activities

Revenue increase and strong cash position in line with expectations

Post-closing events

The information contained in this press release will be commented by the MedinCell management team during an online conference on December 3, 2019. The comments and answers to participants’ questions will be available on invest.medincell.com

Press release related to half-year events is available on MedinCell’s website: https://invest.medincell.com/#news

View source version on businesswire.com:https://www.businesswire.com/news/home/20191203005830/en/

CONTACT: MedinCell

David Heuzé

Communication leader

david.heuze@medincell.com

+33 (0)6 83 25 21 86NewCap

Louis-Victor Delouvrier / Alexia Faure

Investor relations

medincell@newcap.eu

+33 (0)1 44 71 94 94NewCap

Nicolas Merigeau

Media relations

medincell@newcap.eu

+33 (0)1 44 71 94 94

KEYWORD: FRANCE EUROPE

INDUSTRY KEYWORD: PROFESSIONAL SERVICES HEALTH OTHER HEALTH FINANCE GENERAL HEALTH PHARMACEUTICAL BIOTECHNOLOGY

SOURCE: MedinCell

Copyright Business Wire 2019.

PUB: 12/03/2019 11:54 AM/DISC: 12/03/2019 11:54 AM

http://www.businesswire.com/news/home/20191203005830/en